EcoDrugPlus

Glutamate Receptor Ionotropic, Nmda 1

Ensembl ID : ENSORLG00000016452
Gene Symbol: LOC101175170
3 Cross references
176 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 1

Ensembl ID : ENSORLG00000014189
Gene Symbol: LOC101169874
4 Cross references
205 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 2c

Ensembl ID : ENSORLG00000010971
Gene Symbol: LOC101166504
3 Cross references
249 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 2d

Ensembl ID : ENSORLG00000011448
Gene Symbol: LOC101164674
3 Cross references
212 Possible Orthologues:

Glutamate Receptor Ionotropic, Kainate 5

Ensembl ID : ENSORLG00000001149
Gene Symbol: LOC101155942
3 Cross references
229 Possible Orthologues:

Glutamate Receptor, Ionotropic, Ampa 1a

Ensembl ID : ENSORLG00000007719
Gene Symbol: GRIA1A
4 Cross references
251 Possible Orthologues:

Glutamate Receptor, Ionotropic, Ampa 2b

Ensembl ID : ENSORLG00000020342
Gene Symbol: GRIA2B
4 Cross references
224 Possible Orthologues:

Glutamate Receptor, Ionotropic, Ampa 3a

Ensembl ID : ENSORLG00000008662
Gene Symbol: GRIA3A
4 Cross references
251 Possible Orthologues:

Glutamate Receptor, Ionotropic, N-Methyl D-Aspartate 2a, B

Ensembl ID : ENSORLG00000009184
Gene Symbol: GRIN2AB
3 Cross references
98 Possible Orthologues:

Glutamate Receptor, Ionotropic, N-Methyl D-Aspartate 2b, Genome Duplicate B

Ensembl ID : ENSORLG00000004215
Gene Symbol: GRIN2BB
4 Cross references
250 Possible Orthologues:

Glutamate Receptor, Ionotropic, N-Methyl D-Aspartate 2d, A

Ensembl ID : ENSORLG00000005999
Gene Symbol: GRIN2DA
3 Cross references
214 Possible Orthologues:

Glutamate Receptor, Ionotropic, N-Methyl-D-Aspartate 3ba

Ensembl ID : ENSORLG00000011452
Gene Symbol: GRIN3BA
3 Cross references
226 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).